These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 1526090)

  • 1. Hemodynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hypertension.
    Schmitt R; Kleinbloesem CH; Belz GG; Schroeter V; Feifel U; Pozenel H; Kirch W; Halabi A; Woittiez AJ; Welker HA
    Clin Pharmacol Ther; 1992 Sep; 52(3):314-23. PubMed ID: 1526090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris: a multicenter, placebo-controlled study. Ro 40-5967 International Study Group.
    Bakx AL; van der Wall EE; Braun S; Emanuelsson H; Bruschke AV; Kobrin I
    Am Heart J; 1995 Oct; 130(4):748-57. PubMed ID: 7572582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose-response characteristics of mibefradil, a novel calcium antagonist, in the treatment of essential hypertension.
    Oparil S; Kobrin I; Abernethy DR; Levine BS; Reif MC; Shepherd AM
    Am J Hypertens; 1997 Jul; 10(7 Pt 1):735-42. PubMed ID: 9234827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist.
    Petrie JR; Glen SK; MacMahon M; Crome R; Meredith PA; Elliott HL; Reid JL
    J Hypertens; 1995 Dec; 13(12 Pt 2):1842-6. PubMed ID: 8903664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension.
    Oparil S; Bernink P; Bursztyn M; Carney S; Kobrin I
    Am J Cardiol; 1997 Aug; 80(4B):12C-19C. PubMed ID: 9286849
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group.
    Bernink PJ; Prager G; Schelling A; Kobrin I
    Hypertension; 1996 Mar; 27(3 Pt 1):426-32. PubMed ID: 8698449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of a new calcium antagonist, mibefradil (Ro 40-5967), on silent ischemia in patients with stable chronic angina pectoris: a multicenter placebo-controlled study. The Mibefradil International Study Group.
    Braun S; van der Wall EE; Emanuelsson H; Kobrin I
    J Am Coll Cardiol; 1996 Feb; 27(2):317-22. PubMed ID: 8557900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mibefradil, a novel calcium antagonist, in elderly patients with hypertension: favorable hemodynamics and pharmacokinetics.
    Bursztyn M; Kadr H; Tilvis R; Martina B; Oigman W; Talberg J; Kobrin I
    Am Heart J; 1997 Aug; 134(2 Pt 1):238-47. PubMed ID: 9313603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist.
    Kobrin I; Charlon V; Lindberg E; Pordy R
    Am J Cardiol; 1997 Aug; 80(4B):40C-46C. PubMed ID: 9286853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased survival after long-term treatment with mibefradil, a selective T-channel calcium antagonist, in heart failure.
    Mulder P; Richard V; Compagnon P; Henry JP; Lallemand F; Clozel JP; Koen R; Macé B; Thuillez C
    J Am Coll Cardiol; 1997 Feb; 29(2):416-21. PubMed ID: 9014998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocking agent mibefradil in patients with varying degrees of left ventricular systolic dysfunction.
    Rousseau MF; Hayashida W; van Eyll C; Hess OM; Benedict CR; Ahn S; Chapelle F; Kobrin I; Pouleur H
    J Am Coll Cardiol; 1996 Oct; 28(4):972-9. PubMed ID: 8837576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension.
    Oparil S
    Am J Hypertens; 1998 Apr; 11(4 Pt 3):88S-94S. PubMed ID: 9607372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The interaction of the calcium antagonist RO 40-5967 with digoxin.
    Siepmann M; Kleinbloesem C; Kirch W
    Br J Clin Pharmacol; 1995 May; 39(5):491-6. PubMed ID: 7669484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating the safety of mibefradil, a selective T-type calcium antagonist, in patients with chronic congestive heart failure.
    van der Vring JA; Bernink PJ; van der Wall EE; van Velhuisen DJ; Braun S; Kobrin I
    Clin Ther; 1996; 18(6):1191-206. PubMed ID: 9001836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular effects of mibefradil in hypertensive patients with obstructive sleep apnea.
    Heitmann J; Grote L; Knaack L; Köhler U; Hinder M; Peter JH
    Eur J Clin Pharmacol; 1998; 54(9-10):691-6. PubMed ID: 9923569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-anginal and anti-ischemic effects of mibefradil, a new T-type calcium channel antagonist.
    Kobrin I; Bieska G; Charlon V; Lindberg E; Pordy R
    Cardiology; 1998; 89 Suppl 1():23-32. PubMed ID: 9570426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mibefradil, a pharmacologically distinct calcium antagonist.
    Ernst ME; Kelly MW
    Pharmacotherapy; 1998; 18(3):463-85. PubMed ID: 9620098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosolic calcium and lymphoproliferative response during calcium antagonism in men.
    Lijnen P; Fagard R; Petrov V
    Eur J Clin Pharmacol; 1999 Feb; 54(12):911-5. PubMed ID: 10192750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
    Welker HA
    J Pharm Pharmacol; 1998 Sep; 50(9):983-7. PubMed ID: 9811158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antihypertensive effects of mibefradil: a double-blind comparison with diltiazem CD.
    Massie BM; Chrysant SG; Jain A; Weir M; Weiss R; Korrin I
    Clin Cardiol; 1997 Jun; 20(6):562-8. PubMed ID: 9181268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.